Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Non-Current Debt: 2013-2024

Historic Non-Current Debt for Fortress Biotech (FBIO) over the last 12 years, with Dec 2024 value amounting to $58.0 million.

  • Fortress Biotech's Non-Current Debt fell 8.96% to $47.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.8 million, marking a year-over-year decrease of 8.96%. This contributed to the annual value of $58.0 million for FY2024, which is 4.76% down from last year.
  • According to the latest figures from FY2024, Fortress Biotech's Non-Current Debt is $58.0 million, which was down 4.76% from $60.9 million recorded in FY2023.
  • Fortress Biotech's Non-Current Debt's 5-year high stood at $91.7 million during FY2022, with a 5-year trough of $42.9 million in FY2021.
  • Over the past 3 years, Fortress Biotech's median Non-Current Debt value was $60.9 million (recorded in 2023), while the average stood at $70.2 million.
  • In the last 5 years, Fortress Biotech's Non-Current Debt spiked by 113.64% in 2022 and then slumped by 33.66% in 2023.
  • Over the past 5 years, Fortress Biotech's Non-Current Debt (Yearly) stood at $51.7 million in 2020, then decreased by 16.91% to $42.9 million in 2021, then skyrocketed by 113.64% to $91.7 million in 2022, then crashed by 33.66% to $60.9 million in 2023, then fell by 4.76% to $58.0 million in 2024.